<DOC>
	<DOC>NCT01726946</DOC>
	<brief_summary>A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Key Subjects (male and female) must be between the ages of 18 and 60 years at screening Subjects must have genotype 1 Chronic Hepatitis C Subjects must be treatment naïve Subjects must have laboratory values at screening within limits as specified by the protocol Key Evidence of cirrhosis Female subjects who are pregnant or nursing or male subjects with a female partner of childbearing potential who is unwilling to adhere to the contraception requirements, is pregnant or nursing, or planning to become pregnant during the study Any other cause of significant liver disease in addition to hepatitis C Human immunodeficiency virus 1 or 2 Diagnosis of or suspected hepatocellular carcinoma History of organ transplant, with the exception of corneal transplants and skin grafts</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
</DOC>